GLPwatch
Papers (9189)
Page 123 of 154, ranked by citation count.
- Dulaglutide for erectile dysfunction in type 2 diabetes.
- Pharmacological Signatures of the Exenatide Nanoparticles Against Hepatic Ischemia/Reperfusion-induced Pancreatic Injury.
- Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
- iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.
- Silk fibroin hollow microneedle system for sustained transdermal administration of liraglutide: development and characterization.
- The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes.
- Liraglutide modulates ALCAT1-Mediated cardiolipin remodeling to improve cardiac function in obese mice.
- Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic Review.
- Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin.
- Liraglutide modulates lipid metabolism via ZBTB20-LPL pathway.
- Case report: Tirzepatide for mitochondrial diabetes mellitus with a mutation at position 3271 and transient GAD antibody positivity.
- Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists.
- An Increase of Heart Rate and Electrocardiographic Changes after Subcutaneous Liraglutide.
- Insulin secretion decline in Walker-256 tumor-bearing rats is early, follows the course of cachexia, and is not improved by lixisenatide.
- Endocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity.
- Exenatide implant therapy in diabetes.
- Clinical experience with exenatide in a routine secondary care diabetes clinic.
- INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6-month treatment with incretin-based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double-blind, randomised controlled trials (INVESTDIA).
- Understanding the activation mechanism of GLP-1R/GIPR by dual agonist Tirzepatide via molecular dynamics and protein-peptide binding.
- Redistribution of Proximal and Distal Reabsorption of Water and Ions in Rat Kidney After Treatment with Glucagon-Like Peptide-1 Mimetic.
- In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis.
- Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity.
- In brief: New FDA warning of pulmonary aspiration with GLP-1 receptor agonists.
- Multi-omics analysis of hepatic outcomes in T2DM-MAFLD patients treated with semaglutide: a single-centre, longitudinal, data-driven study.
- Problematic Pharmacokinetics: A Case of Recurrent Pancreatitis Post Discontinuation of a Glucagon-Like Peptide 1 Receptor Agonists.
- [Effect of liraglutide on glucagon secretion in obese type 2 diabetic patients].
- Tirzepatide Lowered Blood Pressure in People With Obesity.
- From needles to pills: oral GLP-1 therapy enters the obesity arena.
- Adverse effects with semaglutide: a protocol for a systematic review with meta-analysis and trial sequential analysis.
- Review: Special Issue: <i>Real-world evidence on the use of GLP1 receptor agonists</i>: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.
- Integrating semaglutide into obesity management - a primary care perspective.
- [Tirzepatide : overview of clinical studies SURPASS in type 2 diabetes and SURMOUNT in obesity].
- [Liraglutide protects against nonalcoholic fatty liver disease in ApoE knockout mice with high-fat diet and silenced Acrp30 by increasing AMPK].
- A cost-effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada.
- Exploring beyond numeric weight loss: The metabolic effects of semaglutide.
- Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy.
- REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort.
- Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review.
- GLP- 1 Receptor Agonists in Patients with Cancer are Associated with Reduced All-Cause Mortality and Hospitalization.
- Evaluating Weight Loss Associated with Bariatric Surgery After Liraglutide Use: A Matched Population-Level Retrospective Cohort Study.
- Evaluation of A Novel GLP-1R Ligand for PET Imaging of Prostate Cancer.
- Mixing Pens and the Future of Diabetes Drugs.
- Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.
- Insulin requirements after switching from GLP-1 receptor agonist to dual GIP/GLP-1 receptor agonist in patients with type 2 diabetes mellitus.
- DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
- Design and Biosynthesis of Ornithine 8-Containing Semaglutide Variants with a Click Chemistry-Modifiable Position 26.
- Assessment of innate immune response modulating impurities (IIRMI) in synthetic peptide drugs (liraglutide).
- In adults with BMI ≥27 kg/m<sup>2</sup> and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.
- Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model.
- [Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
- Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes?
- Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature.
- One-year usage patterns of SGLT-2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes in a real-world population.
- Treating with liraglutide an obese patient with type 2 diabetes mellitus and hereditary hemochromatosis.
- Incretin-based therapy for type 2 diabetes mellitus: pancreatic and extrapancreatic effects.
- Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity.
- Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes.
- In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c.
- Liraglutide in type 2 diabetes mellitus.
- The impact of preadmission/prediagnosis use of GLP-1 receptor agonists on COVID-19 mortality in patients with diabetes: A systematic review and meta-analysis.